ICP catalyzing Industry Collaboration

For the past one year, the Industry Collaboration Portal, an industry partnering initiative at Indiana University School of Medicine has been actively pursing research collaboration with pharmaceutical and medical device companies. In this new program ICP brings together researchers from Industry and IUSM to their share their research interests and expertise, and explore potential areas of collaboration. The “scientific exchange” program has resulted in exposure of more than 50 IUSM researchers to Industry leading to a greater mutual understanding of the research at IUSM and the companies involved. This has been particularly beneficial to the local Indiana based healthcare companies. Several companies including, Eli Lilly, Takeda, Cook, Regentec, Biomet and AstraZeneca have participated in the “Scientific exchange”. Leveraging the key strengths areas of medical research at the school, ICP has successfully catalyzed collaboration with Industry. An example is the recent entry into collaboration with Eli Lilly and Company to characterize Diabetes-related disease states using human samples and unique animal models available at Indiana School of Medicine. IUSM researchers are also collaborating with Eli Lilly and Company on projects aimed at identifying new targets for Diabetes and related disorders. Indiana University School of Medicine has established strong research program in the area of diabetes and metabolic disease. These programs will be further expanded at the newly created Indiana Diabetes Center with an award from the National Institute of Health. IUSM researchers have also partnered with Takeda Pharmaceutical on pharmaceutical research in personalized medicine and pharmacometrics. Leveraging on the strong Health informatics and Clinical Translational Sciences programs, ICP has created research partnership with the Indiana based medical device company Zimmer-Biomet.

ICP is catalyzing the formation of a new Indiana Center for Biomedical Innovation (ICBI) which will house the startup companies created based on the innovation from IUSM. Furthermore, in partnership with the SPARK program at Stanford, a new funding and mentoring mechanism is underway to support enhancement of early stage technologies to commercialization. In partnership with Indiana CTSI and Indiana University School of Medicine through the office of the Associate Dean for Entrepreneurship and its Industry Collaboration Portal, and the Indiana Center for Biomedical Innovation (ICBI) at IUHealth the Technology Enhancement Awards is geared to fill the critical gap between innovation and commercialization.